Results 81 to 90 of about 7,099 (210)

Hepatitis B Management in the Middle East: A Narrative Review of Current Antiviral Treatments

Gastrointestinal Disorders
Introduction: Chronic hepatitis B (CHB) is a significant public health issue worldwide, especially in the Middle East region. Around 8% to 20% of patients with CHB develop cirrhosis, which may progress to hepatocellular carcinoma.
Hannah Beck, Nishaanth Dalavaye, Kalaikshiga Kengadaran, Mosammath Monira Khatun, Ria Hitesh Patel, Taif Al-Rubaye, Laith Alrubaiy   +6 more
doaj   +1 more source

2SPD-005 Economical analysis of tenofovir alafenamide versus tenofovir-disoproxil fumarate [PDF]

Section 2: Selection, Procurement and Distribution, 2019
Background Due to the recent commercialisation of the presentations of Tenofovir Alafenamide (TAF) for HIV, there is a need to analyse the costs involved in its introduction into the public health system and its potential impact. Purpose The objective of the study is to assess the cost of using TAF instead of tenofovir-disoproxil fumarate (TDF) in a
M Camean-Castillo, E Rios-Sanchez, MD Gil-Sierra, MP Briceño-Casado, FJ Salmeron-Navas, S Fenix-Caballero, J Diaz-Navarro, C Martinez-Diaz, EJ Alegre-Del Rey, JM Borrero-Rubio   +9 more
openaire   +1 more source

Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Virus Infection in the High‐Replicative Low‐Inflammatory Phase: A 48‐Week Randomized Controlled Trial

Journal of Medical Virology, Volume 98, Issue 5, May 2026.
ABSTRACT Antiviral treatment for chronic HBV infection in the “high‐replicative low‐inflammatory” phase has not been widely recommended. This study aimed to evaluate the safety and efficacy of antiviral therapy in this patient population and analyze peripheral immunological characteristics in relation to treatment response.
Qiumin Luo, Ruixuan Xu, Yeqiong Zhang, Wenxiong Xu, Xiangyong Li, Jing Lai, Jianguo Li, Xingrong Zheng, Hong Deng, Lubiao Chen, Xiang Zhu, Chan Xie, Liang Peng   +12 more
wiley   +1 more source

Persistent risk for new, subsequent new and recurrent hepatocellular carcinoma despite successful anti-hepatitis B virus therapy and tumor ablation: The need for hepatitis B virus cure. [PDF]

, 2019
Hepatitis B virus (HBV) is one of the most significant hepatocarcinogens. The ultimate goal of anti-HBV treatment is to prevent the development of hepatocellular carcinoma (HCC).
Coben, Robert M., Conn, Mitchell I., DiMarino, Anthony J., Hann, Hie-Won, Kroop, Howard, Martin, Aaron, Prieto, Jorge, Shinn, Brianna J.   +7 more
core   +1 more source

The changing face of an epidemic: healthy old age with HIV [PDF]

, 2017
The demographics of the HIV epidemic in the UK have changed significantly. Owing to a steady rate of new diagnoses and improved survival, the population of individuals living with HIV continues to increase.
Chowdhury, M, Nugent, DB, Waters, LJ
core   +1 more source

Tenofovir, Interferon Pathways, and Mucosal Immunity: Implications for People Living With HIV

American Journal of Reproductive Immunology, Volume 95, Issue 5, May 2026.
ABSTRACT Background Antiretroviral therapy (ART) suppresses HIV replication and protects people living with HIV (PLWH) from progressing to AIDS. However, despite ART, many PLWH experience chronic immune activation, which contributes to premature aging and non‐AIDS‐related comorbidities. One reason for this chronic immune activation (CIA) is HIV and its
Florian Hladik, Sean M. Hughes, Claire N. Levy, Rachel L. Creighton, Romel Mackelprang, Germán G. Gornalusse   +5 more
wiley   +1 more source

A United States HIV provider survey of antiretroviral therapy management in people living with HIV with co-occurring conditions

AIDS Research and Therapy
Introduction Simplified HIV treatment guidelines favor integrase strand transfer inhibitors (INSTIs). However, non-infectious comorbidities and co-occurring conditions (i.e.
Sonya Krishnan, Marina B. Martinez Rivera, Christopher K. Lippincott, Maunank Shah   +3 more
doaj   +1 more source

Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort

BMC Infectious Diseases, 2019
Background Tenofovir alafenamide (TAF)-containing combinations were introduced in Switzerland after October 2016 and are recommended over tenofovir disoproxil fumarate (TDF) in patients with osteoporosis or impaired renal function.
Bernard Surial, Matthias Cavassini, Alexandra Calmy, Jan Fehr, Marcel Stöckle, Enos Bernasconi, Bianca Roth, Christoph A. Fux, Helen Kovari, Hansjakob Furrer, Andri Rauch, Gilles Wandeler, the Swiss HIV Cohort Study   +12 more
doaj   +1 more source

Reversible effect on lipids by switching from tenofovir disoproxil fumarate to tenofovir alafenamide and back

AIDS, 2019
The aim of the current study is to assess the effect of tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) on lipids in patients switching from TDF to TAF and back.Retrospective data collection on patients who were initially switched from TDF to TAF and switched back to TDF after generics of TDF became available.In total, 385 patients ...
Milinkovic, A, Berger, F, Arenas-Pinto, A, Mauss, S   +3 more
openaire   +4 more sources

Considerations for the Use of AAV‐based Gene Therapy in HIV‐Positive Individuals With Haemophilia

Haemophilia, Volume 32, Issue 3, Page 584-592, May/June 2026.
ABSTRACT Introduction There is a high prevalence of human immunodeficiency virus (HIV) infection among the haemophilia community due to treatment in the 1970s and 1980s with contaminated clotting factor. Lifelong treatment regimens for haemophilia and HIV are burdensome alone and pose a particular challenge for individuals living with both conditions ...
Jürgen K. Rockstroh, Julia C. Stingl, Marco Stadler, Anja Reichert, Heiner Wedemeyer, Johannes Oldenburg   +5 more
wiley   +1 more source